Investor Presentaiton slide image

Investor Presentaiton

IBI-362 (GLP-1/GCGR) Development Plan Overview Weekly GLP-1/GCGR with Potential BIC Profile for Obesity and Diabetics • Percent CFB in body weight (%), LS mean (SE) IBI-362 Differentiated Advantages Weekly injectable OXM analog via optimized ratio of activation of GLP-1 and Glucagon receptor vs. binding GLP-1 only Dual activation of GLP-1/GCGR may bring multiple metabolic and CV benefit include: 1) blood glucose reduction and weight loss 2) blood pressure and Lipid spectrum improvement; improvement on Liver fat accumulation, inflammation and fibrosis 3) 4) potential CV risk reduction Clinical Highlights Percentage Change in body weight N 0 N + through week 12 -8- 0 4 8 12 Time (weeks) 0.6% CFB in body weight (kg), LS mean (SE) 2 CFB in body weight through week 12 -8. T 0 4 8 12 Time (weeks) Clinical Highlights Promising data of IBI-362 in both weight loss and glucose control in Ph1b studies (Obesity / Diabetes) 1) Results of the Phase 1b study of IBI362 in overweight/obesity (published at ADA 2021 and Eclinical Medicine) showed a favorable safety profile and robust efficacy, including weight loss and multiple metabolic benefits, underlying the advantages and potential of IBI362 as a best-in-class new generation GLP-1 based drug. The observation in extended cohort (higher dose level) were even more efficacious. 2) Results of the Phase 1b study of IBI362 in patients in Type 2 diabetes were very impressive, and will be disclosed at 2021 IDF annual meeting. Clinical IBI-362 Development Program Overview progress Obesity: Released Phase 1b data in obesity at ADA 2021 and Eclinical Medicine FPFD in Phase 2 study for IBI-362 in obesity in 2021.06 0.37 kg IBI362 3.0 mg IBI362 4.5 mg Diabetes: -3.80 kg -5.12 kg -5.77 kg IBI362 6.0 mg Pooled placebo 2021 plan 6 -4.81% -6.05% -6.40% 6 Enrolled first patient in Phase 2 study for IBI-362 in diabetes in 2021.08 Plan to release Phase 1b data in diabetics at IDF 2021 First-in-class OXM3 in Phase 2 stage in China that has demonstrated strong weight deduction effect as well as multiple metabolic benefit in the Phase 1b study for obesity subjects, and demonstrated strong glucose control and other metabolic improvements in the Phase 1b study for diabetics patients. Innovent Confidential Copyright©2021 Innovent Biologics 35
View entire presentation